APA

Juric D., Krop I., Ramanathan R. K., Wilson T. R., Ware J. A., Sanabria Bohorquez S. M., Savage H. M., Sampath D., Salphati L., Lin R. S., Jin H., Parmar H., Hsu J. Y., Von Hoff D. D. & Baselga J. (20180329). Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. : Cancer discovery.

Chicago

Juric Dejan, Krop Ian, Ramanathan Ramesh K, Wilson Timothy R, Ware Joseph A, Sanabria Bohorquez Sandra M, Savage Heidi M, Sampath Deepak, Salphati Laurent, Lin Ray S, Jin Huan, Parmar Hema, Hsu Jerry Y, Von Hoff Daniel D and Baselga José. 20180329. Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. : Cancer discovery.

Harvard

Juric D., Krop I., Ramanathan R. K., Wilson T. R., Ware J. A., Sanabria Bohorquez S. M., Savage H. M., Sampath D., Salphati L., Lin R. S., Jin H., Parmar H., Hsu J. Y., Von Hoff D. D. and Baselga J. (20180329). Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. : Cancer discovery.

MLA

Juric Dejan, Krop Ian, Ramanathan Ramesh K, Wilson Timothy R, Ware Joseph A, Sanabria Bohorquez Sandra M, Savage Heidi M, Sampath Deepak, Salphati Laurent, Lin Ray S, Jin Huan, Parmar Hema, Hsu Jerry Y, Von Hoff Daniel D and Baselga José. Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. : Cancer discovery. 20180329.